Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

Alefacept is approved in the United States as a treatment for chronic plaque psoriasis. Alefacept is unique among treatments for moderate to severe psoriasis because of its selective therapeutic ...

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

A ceramide-containing skin care regimen improves symptoms and quality of life in patients with atopic dermatitis, psoriasis, and xerosis.

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

If we treat aggressively those very early-onset patients, we may be able to prevent chronic disease." Early intervention in plaque psoriasis interrupts the disease's cumulative impact on quality ...